197 related articles for article (PubMed ID: 16687061)
21. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system.
Furlan R; Pluchino S; Martino G
Curr Opin Neurol; 2003 Jun; 16(3):385-92. PubMed ID: 12858077
[TBL] [Abstract][Full Text] [Related]
22. Multiphasic demyelinating disease involving central and peripheral nervous system in a child.
Mariotti P; Batocchi AP; Colosimo C; Lo Monaco M; Caggiula M; Colitto F; Tonali PA; Guzzetta F
Neurology; 2003 Jan; 60(2):348-9. PubMed ID: 12552065
[No Abstract] [Full Text] [Related]
23. Inflammatory mediators in demyelinating disorders of the CNS and PNS.
Hartung HP; Jung S; Stoll G; Zielasek J; Schmidt B; Archelos JJ; Toyka KV
J Neuroimmunol; 1992 Oct; 40(2-3):197-210. PubMed ID: 1331168
[TBL] [Abstract][Full Text] [Related]
24. Chronic inflammatory demyelinating polyneuropathy with multifocal CNS demyelination in an Afrid.
Thomas PK; Valentine A; Youl BD
J Neurol Neurosurg Psychiatry; 1996 Nov; 61(5):529-30. PubMed ID: 8937355
[No Abstract] [Full Text] [Related]
25. Vitamin D in multiple sclerosis and central nervous system demyelinating disease--a review.
Burton JM; Costello FE
J Neuroophthalmol; 2015 Jun; 35(2):194-200. PubMed ID: 25985434
[TBL] [Abstract][Full Text] [Related]
26. [Association of manifestations of chronic post-traumatic stress disorders and disseminated demyelinating disease of the central nervous system].
Djokić G; Bjelica N; Preradović M; Jovicić A; Spirić Z
Vojnosanit Pregl; 1998; 55(2):133-9. PubMed ID: 9623339
[TBL] [Abstract][Full Text] [Related]
27. Acute polyradiculoneuritis associated with demyelinated plaques in the central nervous system: report of a case.
Best PV
Acta Neuropathol; 1985; 67(3-4):230-4. PubMed ID: 4050337
[TBL] [Abstract][Full Text] [Related]
28. [Protein composition and structure of the myelin sheath. Part I].
Pietrucha-Dutczak M; Marcol W; Korczyńska I; Matuszek I; Górka D; Lewin-Kowalik J
Pol Merkur Lekarski; 2003 Sep; 15(87):268-72. PubMed ID: 14679855
[TBL] [Abstract][Full Text] [Related]
29. Beneficial plasma exchange response in central nervous system inflammatory demyelination.
Magaña SM; Keegan BM; Weinshenker BG; Erickson BJ; Pittock SJ; Lennon VA; Rodriguez M; Thomsen K; Weigand S; Mandrekar J; Linbo L; Lucchinetti CF
Arch Neurol; 2011 Jul; 68(7):870-8. PubMed ID: 21403003
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination.
Paz Soldan MM; Rodriguez M
J Infect Dis; 2002 Dec; 186 Suppl 2():S248-53. PubMed ID: 12424705
[TBL] [Abstract][Full Text] [Related]
31. Acute combined central and peripheral inflammatory demyelination.
Katchanov J; Lünemann JD; Masuhr F; Becker D; Ahmadi M; Bösel J; Zschenderlein R; Bamborschke S; Klingebiel R
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1784-6. PubMed ID: 15548509
[No Abstract] [Full Text] [Related]
32. [Candidate cells for remyelinating of the central nervous system].
Nait Oumesmar B; Lachapelle F; Decker L; Avellana-Adalid V; Vitry S; Baron-Van Evercooren A
Rev Neurol (Paris); 1998 Sep; 154(8-9):592-9. PubMed ID: 9809374
[No Abstract] [Full Text] [Related]
33. Chronic steadily progressive central and peripheral predominantly motor demyelination, involving the cranial nerves, responsive to immunoglobulins.
Bentes C; de Carvalho M; de Sá J; Luís ML
Electromyogr Clin Neurophysiol; 1999; 39(1):33-7. PubMed ID: 10076759
[TBL] [Abstract][Full Text] [Related]
34. Peripheral nervous system manifestations of MOG antibody associated disease.
Gupta P; Paul P; Redenbaugh V; Guo Y; Lucchinetti C; Abdulrahman Y; Datta A; Shah S; Klein CJ; Pittock SJ; Flanagan EP; Dubey D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1046-1052. PubMed ID: 38234084
[TBL] [Abstract][Full Text] [Related]
35. Antigen-induced suppression of experimental allergic neuritis in the guinea pig.
McDermott JR; Keith AB
J Neurol Sci; 1980 Apr; 46(1):137-43. PubMed ID: 6246212
[TBL] [Abstract][Full Text] [Related]
36. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.
Mikaeloff Y; Suissa S; Vallée L; Lubetzki C; Ponsot G; Confavreux C; Tardieu M;
J Pediatr; 2004 Feb; 144(2):246-52. PubMed ID: 14760270
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy].
Kubori T; Kaji R
Nihon Naika Gakkai Zasshi; 1998 Apr; 87(4):623-8. PubMed ID: 9627469
[No Abstract] [Full Text] [Related]
38. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease.
Christophi GP; Isackson PJ; Blaber S; Blaber M; Rodriguez M; Scarisbrick IA
J Neurochem; 2004 Dec; 91(6):1439-49. PubMed ID: 15584920
[TBL] [Abstract][Full Text] [Related]
39. The clinical spectrum of the neurological involvement in vasculitides.
Rossi CM; Di Comite G
J Neurol Sci; 2009 Oct; 285(1-2):13-21. PubMed ID: 19497586
[TBL] [Abstract][Full Text] [Related]
40. Clinical and magnetic resonance imaging evidence of brain and spinal cord demyelination in a case of chronic inflammatory demyelinating polyneuropathy.
Gnanalingham KK
J Neurol; 2001 May; 248(5):428-9. PubMed ID: 11437170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
